DRCR.Net Aflibercept vs. Bevacizumab + Utsatt Aflibercept for behandling av CI-DME (DRCR AC)
Randomisert utprøving av intravitreøs aflibercept versus intravitreøs bevacizumab + utsatt aflibercept for behandling av sentralinvolvert diabetisk makulært ødem
Both aflibercept and bevacizumab have been shown to improve vision in eyes with DME. In eyes with DME and at least moderate vision loss, both aflibercept and bevacizumab were also shown to be successful in many eyes. However, aflibercept was shown to be more effective at improving vision, on average, at 1 year and at 2 years. Due to the large cost difference between the two drugs, many clinicians and patients are choosing to initiate treatment with bevacizumab and then switch to aflibercept depending on the eye's response to bevacizumab treatment. However, there is no scientific evidence that this treatment strategy is as effective at improving vision as initiating treatment with aflibercept. Patients and clinicians do not know if this approach ultimately has deleterious effects on visual acuity. If starting with aflibercept is not better than starting with bevacizumab and switching to aflibercept if needed, the potential cost savings to future patients and the health care system would be substantial. However, if starting with aflibercept is better, then patients, clinicians, and health care providers can make informed decisions for how to best treat patients with DME and at least moderate vision loss.
Study Objectives To compare the efficacy of intravitreous aflibercept with intravitreous bevacizumab + deferred aflibercept if needed in eyes with CI DME and moderate vision loss
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
California
-
Campbell, California, Forente stater, 95008
- Retinal Diagnostic Center
-
Glendale, California, Forente stater, 91203
- Macula & Retina Institute
-
Loma Linda, California, Forente stater, 92354
- Loma Linda University Health Care, Department of Ophthalmology
-
Oakland, California, Forente stater, 94609-3028
- East Bay Retina Consultants, Inc
-
-
Florida
-
Fort Myers, Florida, Forente stater, 33912
- National Ophthalmic Research Institute
-
Jacksonville, Florida, Forente stater, 32216
- Florida Retina Institute-Jacksonville
-
Lakeland, Florida, Forente stater, 33805
- Florida Retina Consultants
-
Miami, Florida, Forente stater, 33126
- Retina Macula Specialists of Miami
-
Orlando, Florida, Forente stater, 32806
- Florida Retina Institute
-
Orlando, Florida, Forente stater, 32806
- Central Florida Retina
-
Pinellas Park, Florida, Forente stater, 33782
- Southeast Eye Institute, P.A. dba Eye Associates of Pinellas
-
Plantation, Florida, Forente stater, 33324
- Fort Lauderdale Eye Institute
-
Sarasota, Florida, Forente stater, 34239
- Sarasota Retina Institute
-
Sarasota, Florida, Forente stater, 34233
- Retina Associates of Sarasota
-
Tampa, Florida, Forente stater, 33609
- Retina Associates of Florida, LLC
-
Wesley Chapel, Florida, Forente stater, 33544
- Retina Specialists of Tampa
-
-
Georgia
-
Augusta, Georgia, Forente stater, 30909
- Southeast Retina Center, P.C.
-
Sandy Springs, Georgia, Forente stater, 30328
- Thomas Eye Group
-
-
Illinois
-
Oak Park, Illinois, Forente stater, 60304
- Illinois Retina Associates, S.C.
-
Springfield, Illinois, Forente stater, 62703
- Springfield Clinic, LLP
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46290
- Raj K. Maturi, M.D., P.C.
-
New Albany, Indiana, Forente stater, 47150
- John-Kenyon American Eye Institute
-
-
Kansas
-
Overland Park, Kansas, Forente stater, 66211
- Mid-America Retina Consultants, P.A.
-
Shawnee Mission, Kansas, Forente stater, 66204
- Retina Associates, P.A.
-
-
Kentucky
-
Paducah, Kentucky, Forente stater, 42001
- Paducah Retinal Center
-
-
Louisiana
-
West Monroe, Louisiana, Forente stater, 71291
- Eye Associates of Northeast Louisiana dba Haik Humble Eye Center
-
-
Maryland
-
Hagerstown, Maryland, Forente stater, 21740
- Mid Atlantic Retina Specialists
-
-
Massachusetts
-
Ayer, Massachusetts, Forente stater, 01432
- Valley Eye Physicians and Surgeons
-
Boston, Massachusetts, Forente stater, 02215
- Joslin Diabetes Center
-
-
Michigan
-
Grand Rapids, Michigan, Forente stater, 49546
- Vitreo-Retinal Associates
-
Grand Rapids, Michigan, Forente stater, 49546
- Retina Specialists of Michigan
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63128
- The Retina Institute
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87109
- Eye Associates of New Mexico
-
-
New York
-
New York, New York, Forente stater, 10021
- MaculaCare
-
Rochester, New York, Forente stater, 14620
- Retina Associates of Western New York
-
-
North Carolina
-
Asheville, North Carolina, Forente stater, 28803
- Western Carolina Clinical Research, LLC
-
Charlotte, North Carolina, Forente stater, 28210
- Charlotte Eye, Ear, Nose and Throat Assoc., PA
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44106
- University Hospitals Cleveland Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Dean A. McGee Eye Institute
-
-
Oregon
-
Portland, Oregon, Forente stater, 97221
- Retina Northwest, PC
-
Springfield, Oregon, Forente stater, 97477
- Cascade Medical Research Institute, LLC
-
-
Pennsylvania
-
Monroeville, Pennsylvania, Forente stater, 15146
- Retina Vitreous Consultants
-
Philadelphia, Pennsylvania, Forente stater, 19107-5109
- Retinavitreous Associates, dba; Mid Atlantic Retina
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37909
- Southeastern Retina Associates, P.C.
-
-
Texas
-
Austin, Texas, Forente stater, 78705
- Austin Retina Associates
-
Austin, Texas, Forente stater, 78705
- Retina Research Center
-
Grapevine, Texas, Forente stater, 76051
- Retina Center of Texas
-
Houston, Texas, Forente stater, 77030
- Retina Consultants of Houston, PA
-
Houston, Texas, Forente stater, 77030
- Baylor Eye Physicians and Surgeons
-
Lubbock, Texas, Forente stater, 79424
- Texas Retina Associates
-
McAllen, Texas, Forente stater, 78503
- Valley Retina Institute
-
San Antonio, Texas, Forente stater, 78240
- Retinal Consultants of San Antonio
-
-
Washington
-
Spokane, Washington, Forente stater, 99204
- Spokane Eye Clinic
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- Medical College of Wisconsin
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Participant-level Criteria Inclusion
To be eligible, the following inclusion criteria must be met:
-
Age ≥ 18 years • Individuals <18 years old are not being included because DME is so rare in this age group that the diagnosis of DME may be questionable.
-
Diagnosis of diabetes mellitus (type 1 or type 2)
- Any one of the following will be considered to be sufficient evidence that diabetes is present:
Current regular use of insulin for the treatment of diabetes Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes Documented diabetes by American Diabetes Association and/or World Health Organization criteria
-
At least one eye meets the study eye criteria listed.
-
Able and willing to provide informed consent.
Exclusion
An individual is not eligible if any of the following exclusion criteria are present:
-
Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.
-
A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
- Individuals in poor glycemic control who, within the last four months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next four months should not be enrolled.
-
Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied at the time of study entry.
• Note: study participants cannot receive another investigational drug while participating in the study.
-
Known allergy to any component of the study drug or any drug used in the injection prep (including povidone iodine prep).
-
Blood pressure > 180/110 (systolic above 180 OR diastolic above 110).
• If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.
-
Systemic anti-VEGF or pro-VEGF treatment within four months prior to randomization or anticipated use during the study.
• These drugs cannot be used during the study.
-
For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 24 months.
• Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed.
-
Individual is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the next two years.
Study Eye Criteria The study participant must have at least one eye meeting all of the inclusion criteria and none of the exclusion criteria listed below.
Study participants can have two study eyes only if both eyes are eligible at the time of randomization. For study participants with two eligible eyes, the logistical complexities of the protocol must be considered for each individual prior to randomizing both eyes.
The eligibility criteria for a study eye are as follows:
Inclusion
-
Best corrected Electronic-Early Treatment Diabetic Retinopathy Study visual acuity letter score < 69 (i.e., 20/50 or worse) and ≥ 24 (i.e., 20/320 or better) within eight days of randomization.
-
On clinical exam, definite retinal thickening due to diabetic macular edema involving the center of the macula.
-
Diabetic macular edema present on optical coherence tomography (OCT) within eight days of randomization
- Zeiss Cirrus central subfield: ≥ 290µm in women or ≥ 305µm in men
- Heidelberg Spectralis central subfield: ≥ 305µm in women or ≥ 320µm in men
- Investigator must verify accuracy of OCT scan by ensuring it is centered and of adequate quality
-
Media clarity, pupillary dilation, and individual cooperation sufficient for adequate fundus photographs.
Exclusions
The following exclusions apply to the study eye only (i.e., they may be present for the nonstudy eye):
-
Macular edema is considered to be due to a cause other than diabetic macular edema.
• An eye should not be considered eligible if: (1) the macular edema is considered to be related to ocular surgery such as cataract extraction or (2) clinical exam and/or OCT suggest that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema.
-
An ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition).
-
An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.).
-
Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by three lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).
-
History of an anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema (DME) in the past 12 months or history of any other treatment for DME at any time in the past four months (such as focal/grid macular photocoagulation, intravitreous or peribulbar corticosteroids).
• Enrollment will be limited to a maximum of 25% of the planned sample size with any history of anti-VEGF treatment for DME. Once this number of eyes has been enrolled, any history of anti-VEGF treatment for DME will be an exclusion criterion.
-
History of pan-retinal photocoagulation within four months prior to randomization or anticipated need for pan-retinal photocoagulation in the six months following randomization.
-
History of anti-VEGF treatment for a disease other than DME in the past 12 months.
-
History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior four months or anticipated within the next six months following randomization.
-
History of YAG capsulotomy performed within two months prior to randomization.
-
Aphakia.
-
Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis.
-
Evidence of uncontrolled glaucoma. • Intraocular pressure must be <30, with no more than one topical glaucoma medication, and no documented glaucomatous field loss for the eye to be eligible
Note, combination therapies are considered more than one medication
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Aktiv komparator: Aflibercept Group
2.0 mg intravitreous aflibercept |
Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema. Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert. Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used. The injection will be performed using sterile technique
Andre navn:
|
|
Eksperimentell: Bevacizumab + Deferred Aflibercept Group
1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria |
Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema. Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert. Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used. The injection will be performed using sterile technique
Andre navn:
Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma. Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc. Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used. The injection will be performed using a sterile technique.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean Change in Visual Acuity
Tidsramme: 2 years
|
Area under the curve mean change in the electronic early treatment diabetic retinopathy study visual acuity. Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction. The primary outcome was the time-averaged change in the visual-acuity letter score over a period of 104 weeks. The score was derived by calculating the area under the curve (AUC) over the 104-week period for the change in visual acuity from baseline and dividing by the length of follow-up. |
2 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Antall besøk
Tidsramme: 2 år
|
2 år
|
|
|
Antall øyne i den Bevacizumab-første gruppen som oppfyller byttekriteriene
Tidsramme: Baseline til 12 uker
|
Baseline til 12 uker
|
|
|
Antall øyne i den Bevacizumab-første gruppen som oppfyller byttekriteriene
Tidsramme: Baseline til 24 uker
|
Baseline til 24 uker
|
|
|
Antall øyne i den Bevacizumab-første gruppen som oppfyller byttekriteriene
Tidsramme: Baseline til 52 uker
|
Baseline til 52 uker
|
|
|
Antall øyne i den Bevacizumab-første gruppen som oppfyller byttekriteriene
Tidsramme: Baseline til 104 uker
|
Baseline til 104 uker
|
|
|
Change in Visual Acuity From Baseline
Tidsramme: 2 years
|
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision. |
2 years
|
|
Increase in E-ETDRS Visual Acuity Letter Score
Tidsramme: 2 years
|
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision. |
2 years
|
|
Decrease in E-ETDRS Visual Acuity Letter Score
Tidsramme: 2 years
|
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision. |
2 years
|
|
Visual Acuity
Tidsramme: 2 years
|
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision. |
2 years
|
|
Optical Coherence Tomography Central Subfield Thickness Change From Baseline
Tidsramme: 2 years
|
Measurements made on the Cirrus device were converted to equivalent scores as would be assessed on the Spectralis device with the use of the following formula: Spectralis score = 40.78 + 0.95 × Cirrus score. |
2 years
|
|
Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema
Tidsramme: 2 years
|
Optical coherence tomography (OCT) central subfield thickness equivalents for measurements obtained on Spectral domain OCT machines were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and were 305 μm and 290 μm, respectively on the Cirrus OCT measurement device (Zeiss). |
2 years
|
|
Number of Injections
Tidsramme: 2 years
|
All study injections were counted, including aflibercept injections received among eyes in the bevacizumab first group. |
2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- DRCR.net Protocol AC
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .